CCR5 Ligands in HIV Vaccines

cryopreserved samples versus fresh ones; b) protocol and length of cryopreservation; c)
time elapsed from immunization.
Aim 3: To study antigen specific release of CCR5 ligands in samples obtained from
vaccine trials in humans. These studies will clearly establish the value and utility of our
proposed approach. The studies in this aim will be carried out using samples from the
HVTN (from subjects immunized with canarypox-based immunogens). Chemokine
responses will be established and compared with standard analyses such as antigeninduced proliferative responses, neutralizing antibodies and cytotoxic T cells analyses.
We expect that the accomplishment of these aims will allow for a complete evaluation of
immune responses to vaccines against HIV infection, by potentially contributing the long
sought correlate of protection.
NB: AIM 3 is to be performed in collaboration with the HVTN (pending approval) and
other vaccine networks. In order to perform all of the proposed assays, about 25 x 106
cells/subject are required. See below for specific information on how many cells are
required for each assay. Ideally we would like to receive samples obtained from subjects
immunized with Canarypox-vectored immunogens. See Below for information on
samples needed for the proposed studies.